Progress in Neuro-Psychopharmacology and Biological Psychiatry
August 16, 2016
Steven F. Grieco, Yu-yan Cheng, H. Eldar-Finkelman et al.
ABSTRACT An antidepressant dose of the rapidly‐acting ketamine inhibits glycogen synthase kinase‐3 (GSK3) in mouse hippocampus, and this inhibition is required for the antidepressant effect of ketamine in learned helplessness depression‐like behavior. Here we report that treatment with an antidepressant dose of ketamine (10 mg/kg) increased expression of insulin‐like growth factor 2 (IGF2) in...
Expert Review of Neurotherapeutics
August 10, 2016
Bas T.h. de Veen, Arnt Schellekens, Michel M. M. Verheij et al.
102 citations
Evidence based treatment for Substance use disorders (SUD) includes psychotherapy and pharmacotherapy. However, these are only partially effective. Hallucinogens, such as psilocybin, may represent potential new treatment options for SUD. This review provides a summary of (human) studies on the putative therapeutic effects of psilocybin, and discusses the receptor systems, brain regions and...
JMIR Mental Health
August 8, 2016
Helané Wahbeh, Barry Oken
Background: Mindfulness meditation interventions improve a variety of health conditions and quality of life, are inexpensive, easy to implement, have minimal if any side effects, and engage patients to take an active role in their treatment. However, the group format can be an obstacle for many to take structured meditation programs. Internet Mindfulness Meditation Intervention (IMMI) is a...
The Journal of Alternative and Complementary Medicine
August 2016
Megan S Chesin, Christopher A. Benjamin-Phillips, John G Keilp et al.
To test changes to cognitive functioning among high-suicide risk outpatients participating in an adjunct mindfulness-based intervention combining mindfulness-based cognitive therapy and safety planning (MBCT-S). Ten outpatients with a 6-month history of suicide attempt or active suicidal ideation plus suicidal ideation at study entry received 9 weeks of adjunct group-based MBCT-S. Executive...
Journal of pharmacy practice
August 2016
Joy Brodrick, Brian G Mitchell
A 30-year-old male patient developed a hallucinogen persisting perception disorder (HPPD) after smoking cannabis laced with phencyclidine (PCP) or lysergic acid diethylamide (LSD) 10 years prior to hospital admission. Clinically, he reported seeing vivid, saturated colors and caricature-like objects. The patient described perceiving objects or people in motion as moving faster than normal. He...
Depression and Anxiety
August 1, 2016
S. Sassano-Higgins, D. Baron, Grace Juarez et al.
200 citations
Ketamine was discovered in the 1960s and released for public use in 1970. Originally developed as a safer alternative to phencyclidine, ketamine is primarily used in clinical settings for analgesia and sedation. In recent years, other uses have been developed, including pain management and treatment of asthma and depression. Clinical use of ketamine causes dissociation and emergence delirium....
JMIR Mental Health
July 22, 2016
Pia Kvillemo, Yvonne Brandberg, Richard Bränström
Interventions based on meditation and mindfulness techniques have been shown to reduce stress and increase psychological well-being in a wide variety of populations. Self-administrated Internet-based mindfulness training programs have the potential to be a convenient, cost-effective, easily disseminated, and accessible alternative to group-based programs. This randomized controlled pilot trial...
Mindfulness
July 21, 2016
Maya J. Schroevers, K. Tovote, Evelien Snippe et al.
Depressive symptoms are commonly reported by individuals suffering from a chronic medical condition. Mindfulness-based cognitive therapy (MBCT) has been shown to be an effective psychological intervention for reducing depressive symptoms in a range of populations. MBCT is traditionally given in a group format. The aim of the current pilot RCT was to examine the effects of group-based MBCT and...
Psychopharmacology
July 19, 2016
Kim P. C. Kuypers, Jordi Riba, Mario de la Fuente Revenga et al.
204 citations
INTRODUCTION: Ayahuasca is a South American psychotropic plant tea traditionally used in Amazonian shamanism. The tea contains the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT), plus β-carboline alkaloids with monoamine oxidase-inhibiting properties. Increasing evidence from anecdotal reports and open-label studies indicates that ayahuasca may have therapeutic effects in...
Complementary Therapies in Medicine
July 12, 2016
Sara A Chacko, Gloria Y Yeh, Roger B Davis et al.
Objective: This study aimed to develop and test a novel mindfulness-based intervention (MBI) designed to control weight after bariatric surgery. Design: Randomized, controlled pilot trial. Setting: Beth Israel Deaconess Medical Center, Boston, MA, USA. Interventions: Bariatric patients 1-5 years post-surgery (n=18) were randomized to receive a 10-week MBI or a standard intervention. Main...